Fig. 6. PLOD3 depletion overcomes chemoresistance in vitro.

a Cells were treated with cisplatin for 48 h. Proliferation was detected by cell viability assays. *P < 0.05; **P < 0.01; ***P < 0.001. b A549 and R-H460 cells were transfected with 40 nM siCON or siPLOD3 for 24 h and then treated with cisplatin for another 48 h. The proliferation rate was determined by cell viability assays. *P < 0.05; **P < 0.01; ***P < 0.001. c Cisplatin-treated cells (for 48 h) were analyzed by FACS after AV/PI staining. *P < 0.05; **P < 0.01; ***P < 0.001. d Cell death (of cells treated as in b) as analyzed by AV/PI staining. ***P < 0.001. e Protein levels of cleaved-PARP and active-caspase-3 as determined by western blotting after PLOD3 siRNA and cisplatin treatment. f R-H460 cells were transfected with siRNA in the absence or presence of 5 μM etoposide (ET) or 1 mM hydroxyurea (HU) or 0.1 μg/ml doxorubicin (DX). At 48 h after the drug treatments, the cells were analyzed by FACS after AV/PI staining. *P < 0.05